Pro-atherogenic role of smooth muscle Nox4-based NADPH oxidase

Journal of Molecular and Cellular Cardiology

Volumn 92, Issue , 2016, Pages 30-40

  Tong, Xiaoyong ^a   Khandelwal, Alok R ^b   Wu, Xiaojuan ^a   Xu, Zaicheng ^c   Yu, Weimin ^a   Chen, Caiyu ^c   Zhao, Wanzhou ^d   Yang, Jian ^c   Qin, Zhexue ^e   Weisbrod, Robert M ^b   Seta, Francesca ^b   Ago, Tetsuro ^f   Lee, Kin Sing Stephen ^g   Hammock, Bruce D ^g   Sadoshima, Junichi ^h   Cohen, Richard A ^b   Zeng, Chunyu ^c  

^a CHONGQING UNIVERSITY   (China)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Sino EU Biomedical Innovation Center (SEBIC)   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f KYUSHU UNIVERSITY   (Japan)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Nox4; Smooth muscle; Soluble epoxide hydrolase 2

Indexed keywords

EPOXIDE HYDROLASE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SOLUBLE EPOXIDE HYDROLASE 2; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; NOX4 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NOX4 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLUBLE EPOXIDE HYDROLASE 2 GENE; ANIMAL; AORTA; BIOSYNTHESIS; BLOOD PRESSURE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; TRANSGENIC MOUSE;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING;

EID: 84961328291     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.01.020     Document Type: Article

References (46)

1. Chiu J.-J., Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol. Rev. 2011, 91:327-387. 10.1152/physrev.00047.2009.
2. Nam D., Ni C.-W., Rezvan A., Suo J., Budzyn K., Llanos A., et al. A model of disturbed flow-induced atherosclerosis in mouse carotid artery by partial ligation and a simple method of RNA isolation from carotid endothelium. J. Vis. Exp. 2010, 10.3791/1861.
3. Nam D., Ni C.-W., Rezvan A., Suo J., Budzyn K., Llanos A., et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1535-H1543. 10.1152/ajpheart.00510.2009.
4. Ni C.-W., Qiu H., Rezvan A., Kwon K., Nam D., Son D.J., et al. Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. Blood 2010, 116:e66-e73. 10.1182/blood-2010-04-278192.
5. Simon D.I. Inflammation and vascular injury. Circ. J. 2012, 76:1811-1818. 10.1253/circj.CJ-12-0801.
6. Hopkins P.N. Molecular biology of atherosclerosis. Physiol. Rev. 2013, 93:1317-1542. 10.1152/physrev.00004.2012.
7. Allahverdian S., Chehroudi A.C., McManus B.M., Abraham T., Francis G.A. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation 2014, 129:1551-1559.
8. Allahverdian S., Pannu P.S., Francis G.A. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc. Res. 2012, 95:165-172. 10.1093/cvr/cvs094.
9. Ozaki M.R., de Almeida E.A. Evolution and involution of atherosclerosis and its relationship with vascular reactivity in hypercholesterolemic rabbits. Exp. Toxicol. Pathol. 2013, 65:297-304. 10.1016/j.etp.2011.09.006.
10. Ross R. Atherosclerosis: current understanding of mechanisms and future strategies in therapy. Transplant. Proc. 1993, 25:2041-2043.
11. Lassègue B., Griendling K.K. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 2010, 30:653-661. 10.1161/ATVBAHA.108.181610.
12. Tong X., Khandelwal A.R., Qin Z., Wu X., Chen L., Ago T., et al. Role of smooth muscle Nox4-based NADPH oxidase in neointimal hyperplasia. J. Mol. Cell. Cardiol. 2015, 89:185-194. 10.1016/j.yjmcc.2015.11.013.
13. Barry-Lane P.A., Patterson C., van der Merwe M., Hu Z., Holland S.M., Yeh E.T., et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J. Clin. Invest. 2001, 108:1513-1522. 10.1172/JCI200111927.
14. Judkins C.P., Diep H., Broughton B.R.S., Mast A.E., Hooker E.U., Miller A.A., et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H24-H32. 10.1152/ajpheart.00799.2009.
15. Gray S.P., Di Marco E., Okabe J., Szyndralewiez C., Heitz F., Montezano A.C., et al. Nox1 plays a key role in diabetes accelerated atherosclerosis. Circulation 2013, 127:1888-1902. 10.1161/CIRCULATIONAHA.112.132159.
16. Schürmann C., Rezende F., Kruse C., Yasar Y., Löwe O., Fork C., et al. The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur. Heart J. 2015, ehv460. 10.1093/eurheartj/ehv460.
17. Gray S.P., Di Marco E., Okabe J., Szyndralewiez C., Heitz F., Montezano A.C., et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013, 127:1888-1902. 10.1161/CIRCULATIONAHA.112.132159.
18. Craige S.M., Kant S., Reif M., Chen K., Pei Y., Angoff R., et al. Endothelial NADPH oxidase 4 protects ApoE-/- mice from atherosclerotic lesions. Free Radic. Biol. Med. 2015, 89:1-7. 10.1016/j.freeradbiomed.2015.07.004.
19. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105:1429-1435. 10.1161/01.cir.0000012917.74432.66.
20. Dansky H.M., Charlton S.A., Sikes J.L., Heath S.C., Simantov R., Levin L.F., et al. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1960-1968. 10.1161/01.ATV.19.8.1960.
21. Tong X., Hou X., Jourd'heuil D., Weisbrod R.M., Cohen R.A. Upregulation of Nox4 by TGF{beta}1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. Circ. Res. 2010, 107:975-983. 10.1161/CIRCRESAHA.110.221242.
22. Tong X., Ying J., Pimentel D.R., Trucillo M., Adachi T., Cohen R.A. High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration. J. Mol. Cell. Cardiol. 2008, 44:361-369. 10.1016/j.yjmcc.2007.10.022.
23. Tong X., Schröder K. NADPH oxidases are responsible for the failure of nitric oxide to inhibit migration of smooth muscle cells exposed to high glucose. Free Radic. Biol. Med. 2009, 47:1578-1583. 10.1016/j.freeradbiomed.2009.08.026.
24. Kuroda J., Ago T., Matsushima S., Zhai P., Schneider M.D., Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:15565-15570. 10.1073/pnas.1002178107.
25. Chen K., Kirber M.T., Xiao H., Yang Y., Keaney J.F. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J. Cell Biol. 2008, 181:1129-1139. 10.1083/jcb.200709049.
26. Sanborn R., Hammock B.D. NIH Public Access 2012, 53:7067-7075. 10.1021/jm100691c.1-Aryl-3-(1-acylpiperidin-4-yl)urea.
27. Bayat H., Xu S., Pimentel D., Cohen R.A., Jiang B. Activation of thromboxane receptor upregulates interleukin (IL)-1beta-induced VCAM-1 expression through JNK signaling. Arterioscler. Thromb. Vasc. Biol. 2008, 28:127-134. 10.1161/ATVBAHA.107.150250.
28. Wang H.-W., Liu P.-Y., Oyama N., Rikitake Y., Kitamoto S., Gitlin J., et al. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J. 2008, 22:3561-3570. 10.1096/fj.08-108829.
29. Zuccollo A., Shi C., Mastroianni R., Maitland-Toolan K.A., Weisbrod R.M., Zang M., et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 2005, 112:3001-3008. 10.1016/S0749-4041(08)70346-4.
30. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1996, 27:567-574. 10.1016/0735-1097(95)00522-6.
31. Van Vliet B.N., McGuire J., Chafe L., Leonard A., Joshi A., Montani J.-P. Phenotyping the level of blood pressure by telemetry in mice. Clin. Exp. Pharmacol. Physiol. 2006, 33:1007-1015. 10.1111/j.1440-1681.2006.04479.x.
32. Weisbrod R.M., Shiang T., Al Sayah L., Fry J.L., Bajpai S., Reinhart-King C.A., et al. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension 2013, 62:1105-1110. 10.1161/HYPERTENSIONAHA.113.01744.
33. Lane H.A., Smith J.C., Davies J.S. Noninvasive assessment of preclinical atherosclerosis. Vasc. Health Risk Manag. 2006, 2:19-30. 10.2147/vhrm.2006.2.1.19.
34. Stamatelopoulos K., Karatzi K., Sidossis L.S. Noninvasive methods for assessing early markers of atherosclerosis: the role of body composition and nutrition. Curr. Opin. Clin. Nutr. Metab. Care. 2009, 12:467-473. 10.1097/MCO.0b013e32832f0d99.
35. Zhang L.-N., Vincelette J., Cheng Y., Mehra U., Chen D., Anandan S.-K., et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1265-1270. 10.1161/ATVBAHA.109.186064.
36. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 2000, 87:992-998. 10.1161/01.RES.87.11.992.
37. Elmarakby A.A. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. AJP Regul. Integr. Comp. Physiol. 2012, 302:R321-R330. 10.1152/ajpregu.00606.2011.
38. Davis B.B., Thompson D.A., Howard L.L., Morisseau C., Hammock B.D., Weiss R.H. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2222-2227. (papers://89a9a5ef-0e36-4406-8469-1548b73d210c/Paper/p2833).
39. Sun J., Sui X., Bradbury J.A., Zeldin D.C., Conte M.S., Liao J.K. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res. 2002, 90:1020-1027. (http://www.google.com/search?client=safari&rls=en-us&q=Inhibition+of+vascular+smooth+muscle+cell+migration+by+cytochrome+p450+epoxygenase+derived+eicosanoids&ie=UTF-8&oe=UTF-8/npapers2://publication/uuid/C2905CE1-43C8-4479-90AC-1B28E47E5C79).
40. Deng Y., Theken K.N., Lee C.R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J. Mol. Cell. Cardiol. 2010, 48:331-341. 10.1016/j.yjmcc.2009.10.022.
41. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279. 10.1126/science.285.5431.1276.
42. Revermann M., Schloss M., Barbosa-Sicard E., Mieth A., Liebner S., Morisseau C., et al. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:909-914. 10.1161/ATVBAHA.110.204099.
43. Simpkins A.N., Rudic R.D., Roy S., Tsai H.J., Hammock B.D., Imig J.D. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H795-H806. 10.1152/ajpheart.00543.2009.
44. Ulu A., Davis B.B., Tsai H.-J., Kim I.-H., Morisseau C., Inceoglu B., et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J. Cardiovasc. Pharmacol. 2008, 52:314-323. 10.1097/FJC.0b013e318185fa3c.
45. Manhiani M., Quigley J.E., Knight S.F., Tasoobshirazi S., Moore T., Brands M.W., et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Ren. Physiol. 2009, 297:F740-F748. 10.1152/ajprenal.00098.2009.
46. Anandan S.-K., Webb H.K., Chen D., Wang Y.-X.J., Aavula B.R., Cases S., et al. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg. Med. Chem. Lett. 2011, 21:983-988. 10.1016/j.bmcl.2010.12.042.